Partnering
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn moreCompany Highlights
- Robust pipeline in oncology, autoimmunity and infectious diseases
- Partners include Boehringer Ingelheim, Pfizer and Servier
- Fully-integrated biologics capabilities across product development process
- Strong financial position and blue-chip investor base
- Experienced management team and highly collaborative corporate culture
Overview
Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
Learn moreIn the News
2010 News Archive
December 17, 2010 | Drug Discovery News
MacroGenics Hits Winning Target
October 27, 2010 | Dow Jones Venture Wire
Shrugging Off Bad Break, MacroGenics Sign Boehringer, Pfizer Deals
October 27, 2010 | Fierce Biotech
On a Roll, MacroGenics Inks Pfizer Deal
October 27, 2010 | Gazette
MacroGenics Deal Worth up to $2.1 Billion
October 26, 2010 | BioCentury
MacroGenics in Pair of Antibody Deals
October 26, 2010 | Fierce Biotech
MacroGenics Bounces Back with $2.16B Boehringer Pact
October 26, 2010 | BioWorld Today
Bullseye: MacroGenics Back on Target with Double DART Deals
October 26, 2010 | Genetic Engineering & Biotechnology News
BI Taps MacroGenics in Multibillion-Dollar Deal for Antibody Development
October 26, 2010 | The Pink Sheet
Pfizer, Boehringer Ingelheim Tap MacroGenics in Separate Deals
October 15, 2010 | Genetic Engineering and Biotechnology News
Stem Cell Therapies Make Steady Progress
September 01, 2010 | Chicago Tribune
Clinical Trials Aim to Find Help for West Nile Victims
April 01, 2010 | TrialNet E-News
Can Teplizumab Prevent or Delay Type 1 Diabetes?
News Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All